Diabetes

Study: GLP-1 drugs Linked to 42% Lower Mental Illness Risk

Are GLP-1 drugs a dangerous lifetime dependency or a revolutionary breakthrough for physical and mental health?

Published MAR 20

Study: GLP-1 drugs Linked to 42% Lower Mental Illness Risk

Story

Image credit: Peter Dazeley/Getty Images

The Facts

According to a study published in The Lancet Psychiatry on Wednesday, semaglutide, the active ingredient in GLP-1 medications such as Ozempic and Wegovy, is associated with a 42% lower risk of worsening mental illness compared with periods of non-use.
The Lancet
The Telegraph
The study drew on Swedish health records of nearly 95,000 people diagnosed with depression or anxiety who were taking antidiabetic medications between 2009 and 2022. Semaglutide was linked to a 44% lower risk of worsening depression and a 38% lower risk of worsening anxiety.
BGNES News Agency
Guardian
Semaglutide was also associated with a 47% lower risk of worsening substance use disorder, while GLP-1 receptor agonists as a group were linked to a reduced risk of self-harm. Other GLP-1 drugs, including exenatide and dulaglutide, did not show the same benefits.
The Lancet
Guardian
Liraglutide was associated with an 18% lower risk of worsening mental illness overall and was specifically linked to a lower risk of worsening depression, though its benefits were less pronounced than those observed with semaglutide.
The Lancet
EuroNews
Professor Mark Taylor of Griffith University said: "For GPs and diabetic specialists out there, if you've got someone in your clinic who has obesity or Type 2 diabetes as well as depression or anxiety, it's worth thinking about." The study's authors noted no direct causality could be established.
BGNES News Agency
The Telegraph
Experts urged caution in interpreting the findings. Professor Eduard Vieta of the University of Barcelona said the results "should not yet be interpreted as evidence of a direct therapeutic effect on depression or anxiety," while calling them "reassuring regarding psychiatric safety."
EuroNews
Guardian

Sources Split

LEFT

CENTER

RIGHT

ESTAB
CRIT

CENTER

PRO
ESTAB

The Spin

Narrative A

Semaglutide isn't just a weight-loss drug — it's linked to a 42% lower risk of worsening mental health, a 44% drop in worsening depression and a 47% reduction in substance use disorder. For diabetic patients already facing two to three times higher depression rates, that's a game-changer. The mental health case for GLP-1 drugs is now impossible to dismiss.

Health And Me

Scimex

Narrative B

GLP-1 drugs might show promising numbers, but stopping them triggers "metabolic whiplash" — undoing all cardiovascular benefits in half the time it took to build them. These aren't temporary fixes; they're lifetime dependencies that erode self-regulation and personal discipline. Real health has always required effort, and no pill changes that fundamental truth.

Time Magazine

Suneel Dhand MD on X